Natco launches affordable semaglutide, slashing diabetes drug prices in India

Natco Pharma has launched its generic semaglutide injection in India, marking a significant development in making advanced diabetes and weight-loss treatments more accessible and affordable. The drug, priced at Rs 1,290 per month for the starting doses in multi-dose vial formats, represents a substantial price reduction of up to 90% compared to the innovator brands, Ozempic and Wegovy, previously sold by Novo Nordisk [2, 7, 22]. This launch comes on the heels of the patent expiry for semaglutide in India, which officially occurred on March 21, 2026, paving the way for a wave of generic alternatives [2, 15, 18]. Natco's semaglutide will be available under the brand names Semanat and Semafull in multi-dose vial formats, with pricing starting at Rs 1,290 per month for the 2 mg/1.5 ml and 4 mg/3 ml variants, and Rs 1,750 for the 8 mg/3 ml strength [2, 3, 16]. The company also plans to introduce a pen device version in April 2026, which will be priced between Rs 4,000 and Rs 4,500 per month, depending on the dosage [2, 5, 16]. Natco has emphasized that it is the first company to offer generic semaglutide in a multi-dose vial format with customized syringes in India, which aims to enhance patient accessibility and long-term treatment adherence [5, 16]. The entry of generic semaglutide is expected to trigger an intense pricing war in the Indian pharmaceutical market. Analysts predict that the competition among multiple players will drive prices down significantly, potentially halving the cost of generic versions [2]. Several other major pharmaceutical companies, including Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Zydus Lifesciences, Eris Lifesciences, Mankind Pharma, Alkem Laboratories, and Lupin, are also poised to launch their versions of semaglutide [2, 7, 15, 18, 27]. This increased competition is crucial for India, a country that bears a significant burden of diabetes and obesity, with projections indicating a substantial rise in the number of overweight and obese individuals in the coming decades [15, 28]. Previously, the innovator brands Ozempic and Wegovy were priced at Rs 8,800 and Rs 10,850 per month, respectively, for their starting doses, making them largely unaffordable for a significant portion of the Indian population [2, 4]. The high cost had limited access to these GLP-1 therapies, despite their proven efficacy in managing Type 2 diabetes and aiding in weight management [3, 15]. The introduction of generics at substantially lower price points is therefore a critical step towards democratizing access to these advanced treatments. Natco Pharma received approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture and market generic semaglutide in India in February 2026 [3, 5, 16, 29]. Semaglutide is primarily prescribed for adults with inadequately controlled Type 2 diabetes mellitus, alongside diet and exercise [3, 6]. However, its weight-loss benefits have also led to its widespread use for obesity management, a trend that has gained global attention [1, 18]. While the availability of affordable generics is a welcome development, healthcare professionals have raised concerns about potential misuse and the need for stricter regulation and patient guidance. The surge in availability and reduced cost could lead to the drug being used for cosmetic purposes rather than for its intended medical indications, potentially leading to unmanaged side effects [15, 22]. Doctors emphasize the importance of medical supervision and responsible prescription to ensure patient safety and optimal outcomes [11, 22]. The market for GLP-1 receptor agonists in India has seen significant growth, with sales tripling in the 12 months prior to February 2026, reaching $170 million [28]. Projections suggest the weight-loss drug market in India could grow fivefold by 2030 [28]. The introduction of affordable semaglutide generics is expected to be a major catalyst for this expansion, driving increased patient accessibility and adherence to treatment, thereby addressing the growing public health challenges of diabetes and obesity in India. The overall impact of this market shift will be closely watched, both domestically and internationally, as India emerges as a key player in the global generic semaglutide landscape.

Frequently Asked Questions

Read Full Story on Quick Digest